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Factor VIII is a plasma protein which in the purified state has a mol wt in the range of 1 .1
x 108 (1) . Three distinct properties have been associated with this plasma protein: (a)
factor VIII clot-promoting function (VIII,, .,),' an activity which corrects the coagulation
abnormality of plasma from a patient with classic hemophilia (hemophilia A); (b) factor
VIII antigen (VIIIAGN), an antigen identified in precipitin assays by heterologous
antibodies, normal or increased in hemophilic plasma but decreased in plasma of patients
with von Willebrand's disease; and (c) von Willebrand factor (VIIIvw,), an activity
deficient in von Willebrand's disease which has been identified by an abnormality of the
bleeding time or by in vitro assays of platelet function (ristocetin-induced aggregation and
retention in glass bead columns). Factor VIII refers to a protein or protein system in
normal plasma which is responsible for these three activities. We have previously
demonstrated that cultured human endothelial cells synthesize and release a protein(s)
which has VIIIACN and VIIIVWF activity (2, 3) . Endothelial cells thus synthesize and release
activities which significantly influence platelet function . Recent studies (4, 5) suggest that
the factor VIII system may be closely associated with the platelet surface.
The following studies were undertaken to localize and characterize the separate com-
ponents of the factor VIII system in isolated human platelets. This paper demonstrates
the presence of VIII,,, ;, and VIII,,, in subcellular platelet membrane and granule frac-
tions.
Materials and Methods
Platelet Sub cellular Fractions.
￿
Human platelets were processed as previously described (6). Fresh
platelets (processed the same day as drawn) as well as outdated platelet packs (kindly provided by
the New York Blood Center) were utilized for these studies. Platelet membrane and granule fractions
were prepared by sucrose density gradient ultracentrifugation of platelet homogenates (7) . The
membranes and granules were washed twice in 30 volumes of buffered NaCl solution (pH 7.4, 0.15 M
NaCI-0.0175 M phosphate) containing the broad spectrum protease inhibitor toluene sulfonyl
fluoride (0.4 mM) and the cathepsin inhibitor, N-carbobenzoxy-a-L-glutamyl-L-tyrosine (0.5 mM)
(8) . In some experiments, the platelets were processed from the platelet-rich plasma step to the final
subcellular fractions in the presence of the protease and cathepsin inhibitors. The subcellular
fractions pooled from multiple units of platelets were stored frozen at -20°C. The platelet-soluble
layer was cleared of residual subcellular material by ultracentrifugation at 100,000 g in a Beckman
L2-65 ultracentrifuge (Beckman Instruments Inc., Spinco Div ., Palo Alto, Calif.), dialyzed versus
Ardlie buffer salt solution (8), and stored frozen at -20°C. The buffer was modified from the original
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by omitting glucose, heparin, albumin, and apyrase. Forsolubilization the subcellular fractions were
incubatedfor18 hat 4°Cin Ardlie buffer containing 0.1%Lubrol PX (Sigma Chemical Co., St. Louis,
Mo.). The soluble protein solutions were separated from the residual insoluble material by
ultracentrifugation at 100,000 g for 1 h. The excess Lubrol PX was removed from the supernates
containing the solubilized subcellular proteins by the method of Beckman et al. (9). The soluble
subcellular supernates were stirred for 30 min at 4°C with an equal volume of Amberlite resin
(XAD-2, Mallinckrodt Chemical Works, St. Louis, Mo.) suspendedin 0.01 MTris HCl buffer, pH 7.5,
in orderto absorb theLubrol.Theresinwasthen removedby centrifugation at 1,000gfor10 min. The
protein recovery in the Lubrol PX-solubilized subcellular fractions in multiple experiments varied
between 50 and 60% of the total particulate protein.
Antisera.
￿
Monospecific rabbit antihuman factor VIII was obtained from Behring Diagnostics,
American Hoechst Corp., Somerville. N. J. This antibody precipitates VIII,,,;,,, inhibits VIIIA F of
normal plasma, and inhibits ristocetin-induced platelet aggregation (VIIIVWF) . On immunodiffusion
analysis, this antibody reacted with a single line of identity when tested against normal plasma,
hemophilic plasma, and human factor VIII concentrate (Hemofil®, Hyland Div., Travenol Laborato-
ries, Inc., Costa Mesa, Calif.) . Theantibody did not form a precipitin line with plasma from patients
with severe von Willebrand's disease. The antibody also formed a line of identity with two other
antisera monospecific forfactor VIII (2, 3) when all threewere reacted against factor VIII concentrate
(Hemofil®) .
-1-Globulin Fractions.
￿
-y-Globulin fractions of the antiserum and normal rabbit -y-globulin were
prepared as described by Kolb et al. (10) . The antiserum was dialyzed for 24 h at 4°C against 500 vol-
umes of sodium phosphate buffer (0.01 M phosphate, pH 7.0). After removal of insoluble protein by
centrifugation at 3,000 gfor 30 min, the dialyzed sample was applied to a 1.5 x 28.5 cm TEAE-cellu-
lose column equilibrated with the dialysis buffer and the breakthrough protein collected and concen-
trated by precipitation at 0°C with ammonium sulfateat 50% saturation. The precipitate waswashed
three times with 50% saturated ammonium sulfate, dissolved, and dialyzed against 0.15 M NaCl. In-
soluble y-globulin preparations were prepared by coupling the isolated -1-globulin to cyanogen bro-
mide-activated Sepharose 4B (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) (11) .
Semipurified Plasma Factor VIII. Semipurified plasma factor VIII was prepared from a
commercially availablefactor VIII concentrate (HemophilO). 20 ml of Hemophilc containing 500 Uof
VIII,,., was chromatographed on a 5 x 80 cm Sepharose 4B column in phosphate-buffered saline
(0.145 M NaCl, 0.01 M phosphate, pH 7.4) at room temperature at an elution rate of 80 ml/h. The
void volume was determined with Blue Dextran2000 (Pharmacia Fine Chemicals, Inc.). Void volume
fractions were concentated approximately 20-fold using a hollow fiber ultrafilter device (Bio Fiber
80-Minitube, Bio-Rad Laboratories, Richmond, Calif.). The final preparation which contained 0.32
mg/ml protein had32 U ofVIII,, cc, /ml as determined by radioimmunoassay (kindly performed by Dr.
Leon Hoyer, University of Connecticut) (12) . On sodium dodecyl sulfate (SDS) acrylamide gel elec-
trophoresis after reduction with dithiothreitol, 60-70% of the protein in this preparation as deter-
mined by densitometric scan movedas asingle band in themolwt rangeof 230,000.
Quantitative Immunoelectrophoresis of VIIIAC,, in Subcellular Fractions .
￿
This wascarried out by
a modification of the Laurell quantitative immunoelectrophoretic technique as described by
Zimmermanet al. (13). Theantiserumwasdiluted in theagarose 1:50. 10 ul of thesolution containing
the antigen were deposited in 3-mm diameter wells. A standard curve was constructed by testing
whole plasma in serial dilutions. 1 U of the antigen is the amount present in 1 ml of pooled normal
plasma prepared from 10 normal male adult subjects.
Immunoabsorption of Subcellular VHIAc ,.,. 1 ml of solubilized membrane protein solution
(varying in different experiments from 2 to 2.25mg/ml) was incubated at room temperature with 0.5
ml insolubilized anti-VIII Sepharose (3.5 mg globulin). The mixturewasshaken at room temperature
on arotatingtumbler(Labindustries, Berkeley, Calif.) for 2h. Theclearmembrane protein supernate
was removed after centrifugation at 8,000 g for 20 min. Identical insoluble antibody immunoabsorp-
tion studies were performed with thesoluble granule protein solution (1-2.2 mg/ml). Control immuno-
absorption studies of the subcellular fractions were performed using insoluble normal rabbit -y-globu-
lin.
SDS Polyacrylamide Gel Electrophoresis.
￿
SDSpolyacrylamide gelelectrophoresis (5% gels) was
performed as described by Weber and Osborn (14) . Samples for analysis were added to an equal
volume of a solution containing 10 M urea, 2% SDS, and 14 mM dithiothreitol and boiled for5 min.RALPH L. NACHMAN AND ERIC A. JAFFE
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Precipitates for gel electrophoresis were solubilized in 100 ul of 10 M urea-2% SDS-14 mM
dithiothreitol and boiled before application on the gel. Thegels were stained with Coomassie brilliant
blue. Densitometric scans of gels were carried out in a Gilford Model 240 spectrophotometer
equipped with agel scanning attachment (Gilford Instrument Laboratories, Inc., Oberlin, Ohio) anda
Densicord recorder equipped with an integrator (Photovolt Corp., New York) .
The molecular weight of VIII,,,, was determined by SDS acrylamide gel electrophoresis as
described (14). Molecular weight markers included phosphorylase A, mot wt 94,000 (Sigma Chemical
Co.); ovalbumin, motwt 43,000 (Pharmacia Fine Chemicals Inc.); chymotrypsin, mot wt 25,000 (Cal-
biochem, San Diego, Calif.); and a-2-macroglobulin subunit, mot wt 185,000 (Kindly provided by Dr.
Peter Harpel).
Subcellular Platelet VIIIWF Activity.
￿
This was assayed by the ristocetin method as previously
described (3, 15, 16) . Washed normal human platelets were prepared using the Ardlie buffer salt
system (8). For these purposes the buffer was modified by omitting calcium and adding I mM
adenosine to all wash solutions and increasing the number of washes to five. Theassay wasperformed
in an aggregometer (Payton Dual Channel, Payton Assoc., Buffalo, N. Y.) using 350 al of washed
platelets, 50 al of the material to be tested, and ristocetin (Abbott Laboratories, Chemical Marketing
Div., Chicago, Ill .) at a final concentration of 1 .5 mg/ml.
Ristocetin-Platelet Membrane Protein Interaction.
￿
This was studied by comparing the SDS gel
electrophoresic patterns of the solubilized membrane polypeptides after incubation with varying
amountsof ristocetin. The membrane protein solutions were incubated with the ristocetin for I h at
37°C and the precipitate pelleted at 8,000 g for 20 min. The supernates were incubated with equal
volumes of the urea-SDS-dithiothreitol solution, boiled, and analyzed by polyacrylamide gel
electrophoresis. Similarly theprecipitates were solubilized in 100ul of the same solution, boiled, and
analyzed on disc gels.
Subcellular Platelet VIII,,,,, Activity.
￿
This was assayed by a one-stage method using congenital
VIII, .,-deficient human plasma as substrate (17) . Pooled normal human plasma was used as the
standard and VIII,,., values expressed as units per milliliter. 1 U ofVIII,, ., is defined as that activity
present in 1 ml of pooled platelet-poor plasma from 10 or more normal donors.
Results
Quantitation ofFactor VIII,,,,,, in Platelet Subcellular Fractions.
￿
The antigen
was detected in the soluble protein obtained from both the subcellular granule
and membrane fractions (Table 1) . No antigenic activity was identified in the
cytosol-soluble fraction. The V111AGN in the subcellular fractions reacted identi-
cally to the plasma VIII,,;, standard in quantitative immunoelectrophoresis .
When the heights of the rocket precipitins obtained from serial dilutions of the
membrane and granule VIIIACN and the plasma standard were graphically
plotted, the three lines connecting the three different sets of points were parallel.
TABLE I
Quantitation of VIIIAGN in Platelet Subcellular Fractions
* 1 Uof VIII A G 11 is defined as the amount ofVIII ACN present in 1 ml pooled
platelet-poor plasma from 10 normal donors.
$Calculated from the protein distribution of platelet fractions obtained
from 1 unit (450 ml) of blood. Granules 22%, and membranes 4.3% (7). 1
U of platelets contains 150 mg protein (18, 19).
Fraction Protein VIIIAI .N* VIVA"$
mg/ml U1mg U/ml blood
Granules 1.13 1.54 0.113
Membranes 2-36 3 .39 0.048
Soluble 2.12 0 -1104
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The VIIIAGN measured was the same using fresh as well as outdated platelets.
Both subcellular fractions were considerably enriched in factor VIIIAGN when
compared to plasma. The plasma standard contained 1 U VIII AGN/70 mg protein
(1 ml platelet-poor plasma) or 0.014 U/mg. Thus the platelet granules were
enriched over 100-fold and the membranes were enriched over 200-fold in VIIIAGN
compared to plasma. From previously published data it was possible to calculate
the VIIIAGN content of whole blood attributable to the platelet fractions. Isolated
platelet granules and membranes account for 22 and 4.3% respectively, of the
platelet protein separated from 1 unit (450 ml) of blood (7) and 1 unit of platelets
is equivalent to 150 mg of protein (18, 19) . Thus 1 ml of whole blood contains 73
ug of granule protein. This amount of granule protein contains 0.113 U Of VIIIAGN
(Table 1) . Similarly, 1 ml of whole blood contains 14 lag of membrane protein
Q150 x 0.043]/450) . This amount of membrane protein contains 0.048 U of
VIIIAGN (Table 1) . Thus the platelets in 1 ml of whole blood contain approxi-
mately 15% of the amount of VIIIAGN present in 1 ml of platelet-poor plasma .
Identification of Factor VIIIAGN Subunit in Platelet Subcellular
Fractions. For these studies, the subcellular fractions (isolated membranes or
granules) were solubilized in Lubrol and then exposed to Amberlite to remove the
excess detergent. The residual soluble proteins were incubated with insoluble
rabbit antibody to human factor VIII and the immune complex removed by
centrifugation. The absorbed and unabsorbed protein solutions were analyzed by
SDS acrylamide gel electrophoresis for the presence or absence of a protein
which moved with the same electrophoretic mobility as partially purified plasma
factor VIII A GN.
IMMUNOABSORPTION OF THE SOLUBLE PLATELET MEMBRANE PROTEINS .
￿
The soluble
platelet membrane preparation contained numerous polypeptide bands (Fig . 1),
one of which moved with the same electrophoretic mobility as partially purified
plasma factor VIIIAGN (approximate mol wt 230,000) . This latter band was the
only one removed from the membrane protein solution by absorption with
insoluble anti-VIII. There was no effect on the membrane protein solution after
exposure to insoluble normal rabbit -y-globulin .
IMMUNOABSORPTION OF THE SOLUBLE PLATELET GRANULE PROTEINS.
￿
The soluble
platelet granule preparation contained numerous polypeptide bands (Fig. 2), one
of which moved with the same electrophoretic mobility as partially purified
plasma factor VIIIAGN. This latter band was the only one removed from the
granule protein solution by absorption with insoluble anti-VIII. There was no
effect on the membrane protein solution after exposure to insoluble normal
rabbit 1'-globulin.
CYTOSOL PROTEINS .
￿
The soluble cytosol platelet protein preparation contained
numerous polypeptides (Fig. 3) ; however, there was no band in the factor VIII
230,000 mol wt region.
Subcellular Platelet VIIIIWF.
￿
VIIIIWF was assayed by determining the pres-
ence of an activity in the various subcellular protein solutions which supported
ristocetin-induced aggregation of washed normal human platelets. Soluble
subcellular granule and membrane protein supported ristocetin-induced aggre-
gation while the soluble cytosol fraction did not (Fig. 4) . Washed platelets in
buffer did not aggregate after the addition of ristocetin alone (not shown) . No
attempts were made to quantitate the VIIIIWFactivity in theseparate fractions.RALPH L. NACHMAN AND ERIC A. JAFFE
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FIG. 1 .
￿
Immunoabsorption of platelet membrane factor VIII AGr, . Densitometric scans ofSDS
acrylamide gels of: (a) membrane soluble protein solution -50,ul (2 .2 mg/ml) wasadded to 50
ul of a solution containing 10M urea, 2% SDS, and 14 mM dithiothreitol andboiledfor5min .
25 jut bromphenol blue dyemarker was added and 50 Fl (44,ug) applied to the gel . (b) Identical
experiment as described in a except that the membrane protein solution was first absorbed
with insoluble anti-VIII . (c) Semipurified plasma factor VIII (4 wg) . Coomassie blue stained
gels with anode to the right . The vertical dashes enclose the factor VIIIA,,, subunit region .
Platelet Membrane Protein Ristocetin Interaction.
￿
An attempt was made to
monitor the ristocetin-platelet membrane protein reaction by comparing the
SDS gel electrophoretic patterns of the membrane polypeptides after exposure to
variable amounts of ristocetin (Fig . 5) . Ristocetin precipitated membrane
proteins including VIIIAGN with the maximum effect occurring at a ristocetin
concentration of 1 mg/ml . This appeared to be a nonspecific reaction as different
concentrations of ristocetin precipitated the same proportions of both factor
VIIIAGN and an unrelated membrane protein labeled "X" (Fig . 6) .
Subcellular Platelet Factor VIIIAHF .
￿
None of the subcellular fractions con-
tained V111AHF as assayed in an VIIIAHF-deficient human plasma system (Table
II) . The inhibitors used in processing the platelet subcellular fractions (N-car-
bobenzoxy-a-L-glutamyl-L-tyrosine and toluene sulfonyl fluoride) had no effect
on VIIIAHF as assayed in the human plasma standard .
Discussion
Subcellular fractions derived from normal human platelets have been shown in
these studies to contain significant amounts of VIIIAGN and VIIIvw,activity . The1106
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FIG, 2.
￿
Immunoabsorption of platelet granule factor VIII IG,,. Densitometric scans of SDS
acrylamide gels of: (a) granule soluble protein solution-50,u1(1.9 mg/ml) wasadded to 50 wl of
asolution containing 10 M urea, 2% SDS, and 14 mM dithiothreitol and boiled for5min. 25 Pl
bromphenol blue dye marker was added and50IAl(38 ug) ofthesolution applied to thegel. (b)
Identical experiment as described in a except that the membrane protein solution was first
absorbed with insoluble anti-VIII. (c) Semipurified plasma factor VIII (4 hg). Coomassieblue
stained gels with anode to the right. The vertical dashes enclose the factor VIII,,," subunit
region.
VIII,,,,,, was identified in the subcellular fractions by quantitative immunoelec-
trophoresis and immunoabsorption using insoluble antibodies. The specificity of
these techniques is dependent on the specificity of the antiserum used. The
rabbit anti-VIII employed in these studies had the same inhibitory properties as
a highly specific rabbit anti-VIII which we used and characterized previously (2).
On immunodiffusion analysis, the rabbit anti-VIII reacted with a single line of
identity when tested against human plasma, hemophilic plasma, and a concen-
trate of human plasma factor VIII but did not form a precipitin line with plasma
from patients with severe von Willebrand's disease. The antibody also formed a
line of identity with two other antisera monospecific for factor VIII (2, 3) when all
three were reacted against factor VIII concentrate. This lack of a precipitin line
against von Willebrand's plasma strongly suggests that the anti-VIII sera did not
contain contaminant antibody against cold-insoluble globulin since patients with
von Willebrand's disease have normal plasma levels of cold-insoluble globulin
(20). This negative finding is important because on SDS acrylamide gel electro-
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FIG. 3.
￿
Polypeptides of platelet cytosol-soluble subcellular fraction. Densitometric scans of
SDS acrylamide gels of: (a) cytosol protein solution - 50 Al (2 mg/ml) was added to 50,ul of a
solution containing 10 M urea, 2% SDS, and 14 mM dithiothreitol, andboiled for 5 min. 25 jl
bromphenol blue dye marker wasadded and 50 ul (40 leg) of the solution added to the gel. (b)
Semipurified plasma factor VIII (4 jug). Coomassie blue stained gels with anode to the right.
The vertical dashes enclose the factor VIII,,,;, subunit region.
phoresis after reduction, cold-insoluble globulin also has a mol wt of approxi-
mately 230,000.
Analysis of the membrane-and granule-soluble protein fractions by SDS
acrylamide gel electrophoresis demonstrated a polypeptide in both fractions with
the same molecular weight as human plasma factor VIII. Insolubilized rabbit
anti-VIII removed only this peptide from the membrane and granule protein
preparations . In other work we have shown that the insoluble anti-VIII removed
only a band of the same molecular weight from a preparation of concentrated
human plasma factor VIII.2 These observations strongly suggest that the
molecular species in the platelet fractions is identical to human plasma VIII,,,.
VIII, was demonstrated in the platelet subcellular fractions bythe presence of
an activity in the solubilized protein solutions which supported ristocetin-
induced aggregation of washed platelets. No VIII,,,, was detected in these
preparations.
Recent studies by others have also suggested that plasma VIIIAUN and VIIIv,F
activity is available on the platelet surface (4, 5). Our studies demonstrate that
the intracellular platelet granule population contains a significant reservoir of
platelet VIIIIGN and VIIIvw,. It is possible that granule VIII,,., and VIIIvw,
serves as a storage source of surface membrane VIIIAIN and VIIIv,F. Weiss et al.
(21) have shown that factor VIII, which is necessary for ristocetin-induced1168
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FIG . 4 . Ristocetin-induced aggregation of washed normal platelets . G, granule protein
solution ; M, membrane protein solution ; and S, soluble layer from platelet subcellular
fractionation . Protein was 2 mg/ml in the three solutions . 350 Al of washed platelets (300,000/
Al) and 50 pl of the test protein solution were mixed in the cuvette for approximately 60 s and
then ristocetin was added at zero time as 20 pl of a 30 mg/ml solution (final concentration 1.5
mg/ml) .
FIG . 5 .
￿
SDS acrylamide gel electrophoresis of membrane protein solutions (S, supernate and
P, precipitate) after exposure to variable amounts of ristocetin as indicated for 60 min at 37°C .
The precipitates were pelleted and processed as described in Fig. 1 . 50 X11 were applied to the
gels . 45 pl of the residual supernates were mixed with 50 al of the urea SDS dithiothreitol
solution and processed as described in Fig.l . 50 pl of solution were applied to the gel . VIII
indicates the position of V111AGN . X is an unidentified membrane band whichwascompared to
V111IGN in Fig . 6 .
aggregation, is removed from the platelets by repeated washing but that some
remains within the platelet and is subsequently made available in a washed
buffer system (16) . Similarly, Howard et al . (4) have shown that lysed platelets
contain greater amounts of V111AGN than the corresponding suspension of whole100
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FIG. 6.
￿
Densitometric scan of VIIIAGr, compared to an unidentified membrane band "X" in
the ristocetin membrane protein precipitates shown in Fig. 5. The density of the respective
bands was compared to the amounts present in an equivalent concentration of membrane
protein solution unexposed to the ristocetin .
TABLE II
VIIIANF in Platelet Subcellular Fractions
* 1 U of VIIIA F is defined as the amount ofVIIIAF present in 1 ml pooled
platelet-poor plasma from 10 normal donors.
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platelets. It is not clear from our studies whether the intracellular platelet
VIIIAGN and VIIIVWF are present in a specific granule compartment.
The total amount of platelet VIIIAGN is surprisingly large in terms of that
amount present in normal platelet-poor plasma. Thus the platelets in 1 ml of
blood contain approximately 15% of the VIIIAGN present in 1 ml of platelet-poor
plasma (Table I) . This should be compared to platelet fibrinogen which also
occupies a plasma membrane and intracellular granule compartment (22) .
Platelet fibrinogen represents approximately 10% of the total platelet protein
(19) . Thus 1 ml of blood contains approximately 33 jug of platelet fibrinogen
which represents roughly 1% of the fibrinogen in 1 ml of platelet-poor plasma .
The large relative amounts of VIII,,,,,,, (and presumably equally large amounts of
VIIIvw ,) intimately associated with human platelets further emphasizes the
importance of this protein(s) in normal hemostasis .
The relationship of the factor VIII system to normal platelet physiology has
Fraction Protein VIIIAF*
mg/ml U/ml
Granules 1 .13 <0.01
Membranes 2 .36 <0.01
Soluble 2 .12 <0.011110
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been partially clarified in recent years by the study of patients with von
Willebrand's disease. This genetically transmitted bleeding disorder is character-
ized by a decreased level of plasma factor VIII and a prolonged bleeding time
(23). The prolonged bleeding time in most patients is closely correlated with a
decreased level of factor VIIIvw, as measured by the ristocetin assay (16). Our
recent studies which demonstrate that endothelial cells synthesize and release
VIII,,r, (2) and release VIIIvw, (3), a protein which significantly influences
normal platelet function, further substantiate the importance of platelet-endo-
thelial cell interactions in normal hemostasis (24). The present studies clearly
demonstrate that VIIIvw, activity is present on the platelet membrane . A
potential physiologic implication ofour observations is that circulating platelets
normally adsorb endothelial cell-synthesized VIII, which in some unknown
manner enables the platelet to interact with damaged vessel surfaces. Our
contention is supported by a recent immunofluorescence study showing that
endothelial cells in patients with severe von Willebrand's disease do not contain
VIII,,,, (25). The precise in vivo physiologic counterpart of defective ristocetin
aggregability and diminished platelet adhesiveness to glass bead columns is not
known. However, it has been recently demonstrated that platelets in the blood of
patients with von Willebrand's disease adhere poorly to the subendothelial
surface of rabbit aorta (26). The role of the intracellular granule storage site of
VIIIv,, in this hemostatic process remains to be clarified. The only other cell
system in the body, besides endothelial cells, whichstains forVIII,,,,,,with highly
specific antisera are megakaryocytes and platelets (27). Thus at least theoreti-
cally these cells might also synthesize VIII,,,,,. Platelets, however, have no DNA
and only a vestigial protein synthetic apparatus (18). Whether megakaryocytes
synthesize VIIIAGN remains to be determined .
One ofthe more intriguingand puzzlingfeatures offactor VIII physiology is the
role of ristocetin in inducing platelet aggregation. Our studies demonstrated that
ristocetin precipitated membrane VIIIAGN in a relatively nonspecific reaction. It
is not clear how this precipitation reaction involving soluble proteins relates to
the induction of the aggregation response in the presence of whole cells and
surface VIII,,,,. One possibility is interaction and possible modification of
VIII, carbohydrate side chains. Studies on bovine plasma factor VIII have
indicated that the integrity of carbohydrate side chains on the VIII molecule(s)
are necessary for subsequent aggregation responses (28, 29). Thus bovine plasma
factor VIII preincubated with galactose oxidase no longer induced platelet aggre-
gation. However, human plasma factor VIII preincubated with neuraminidase
supported platelet aggregation in the absence of added ristocetin (30). These
observations raise the possibility that ristocetin alters platelet surface VIIIVwF SO
as to sterically reorient unavailable sites or mask or alter carbohydrate side
chains, thus allowing the protein to support cell to cell interactions.
Finally, our studies again raise some unanswered questions regarding the
macromolecular complex structure of the factor VIII system. Why don't platelets
contain subcellular VIIIAF? One possibility which has to be considered is that
the procoagulant site (the AHFactivity) was destroyed ordamaged inthe process
ofthe preparation of the subcellular fractions. We have previously demonstrated
that platelets contain potent intracellular proteases such as cathepsin A whichWe wish to thank Dr . Peter Harpel for his helpful suggestions and Barbara Ferris for her invaluable
technical assistance .
Received for publication 28 January 1975 .
RALPH L . NACHMAN AND ERIC A . JAFFE
￿
111 1
might destroy the procoagulant activity (31) . However, when platelet subcellular
fractions were processed in buffer containing inhibitors of both cathepsin and
proteolytic enzymes, VIIIA.F was still undetectable . The use of fresh platelets
(processed the same day as drawn) as well as outdated platelet packs had no
effect on the presence or absence of VIII AHF activity in the platelet fractions . It is
thus unlikely that proteolytic degradation occurred due to protracted in vitro
storage . The absence of the procoagulant activity might also be due to
dissociation or masking of a critical site due to proteolytic or other effects of
platelets on the VIII system both in vivo and in vitro before fractionation and the
addition of the protease inhibitors . Another possibility which is raised by our
previous studies (2, 3) is that the factor VIII system is a macromolecular complex
with VIIIAGN and VIIIvwF activity residing on one molecular species and VIIIA1F
residing on another molecular species .
We suggest as a working hypothesis that endothelial cells synthesize and
release and platelets adsorb a carrier or inactive precursor molecule which
because it possesses both VIIIAGN and VIIIvwF is able to support normal platelet
function . This precursor as it circulates in the plasma is converted to that
configuration necessary for VIIIAHF activity after interaction at a remote site
either through contact with a second cell type or by interaction with one or more
plasma enzymes. The clarification of these relationships awaits further study .
Summary
Subcellular membrane and granule fractions derived from human platelets
contain factor VIII antigen and von Willebrand factor activity but not factor VIII
procoagulant activity . Circulating platelets constitute a significant reservoir of
plasma factor VIII antigen, containing approximately 15% of the amount of
factor VIII antigen present in platelet-poor plasma . The antibiotic ristocetin,
which aggregates human platelets in the presence of von Willebrand factor,
nonspecifically precipitates platelet membrane factor VIII antigen . Thus normal
platelets contain surface-bound as well as internally stored von Willebrand
factor, a protein synthesized by endothelial cells which is necessary for normal
platelet function in vivo .
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